| GeneLibs

题目:: Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
作者:: Massarweh(Suleiman),Schiff(Rachel)
状态:: 发布时间2007-04-03 , 更新时间 2007-12-03
期刊:: Clin Cancer Res
摘要:: Two thirds of breast cancers express the estrogen receptor (ER), which contributes to tumor development and progression. ER-targeted therapy is therefore widely used in breast cancer to inhibit signaling through ER and disrupt breast cancer growth. This therapeutic strategy, particularly using the antiestrogen tamoxifen, is proven to increase the cure rates in early breast cancer, improve patient outcomes in advanced disease, and reduce breast cancer incidence in the prevention setting. Despite the recent integration of more powerful endocrine agents into breast cancer care, resistance to all forms of endocrine therapy remains a major problem. New insight into ER biology and progress in understanding resistance mechanisms, mediated by molecular crosstalk between ER and various growth factor signaling pathways, are generating tremendous promise for new therapeutic opportunities to target resistance and improve breast cancer disease outcomes.
语言:: eng
DOI:: 10.1158/1078-0432.CCR-06-2540

文献库文献相关信息